CAM
STML

ClariVest Asset Management’s Stemline Therapeutics, Inc. STML Stock Holding History

ClariVest Asset Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-14,834
Closed -$672K – 668
2013
Q3 		$672K Buy
+14,834
New +$484K 0.03% 244

Other funds holding STML

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SCA
SAC Capital Advisors Stamford, Connecticut $19.3B AUM 31.93% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

ClariVest Asset Management's STML Position: Q4 2013 in Review

ClariVest Asset Management sold out of Stemline Therapeutics, Inc. (STML) in Q4 2013, closing a stake of 14,834 shares — an estimated $672K sold.

ClariVest Asset Management first reported a position in STML in Q3 2013 and held it in 1 quarter. The position peaked at $672K in Q3 2013. 69 funds tracked by Wall St. Rank hold STML as of Q4 2013.

  • ClariVest Asset Management reported no remaining Stemline Therapeutics, Inc. position as of Q4 2013 after selling out during the quarter.
  • ClariVest Asset Management sold 14,834 Stemline Therapeutics, Inc. shares in Q4 2013, an estimated $672K.
  • ClariVest Asset Management first reported a position in Stemline Therapeutics, Inc. in Q3 2013 and held it in 1 quarter.
  • ClariVest Asset Management's Stemline Therapeutics, Inc. position peaked at $672K in Q3 2013.
  • 69 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2013.

Based on ClariVest Asset Management's 13F filing for Q4 2013, filed 10 Feb 2014.